Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IGHE |
Clinical data | |
Other names | QGE031 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6534H10000N1716O2038S44 |
Molar mass | 146612.49 g·mol−1 |
Ligelizumab ( INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. [1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator. [2] [3]
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma [4] concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo. [5]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | IGHE |
Clinical data | |
Other names | QGE031 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6534H10000N1716O2038S44 |
Molar mass | 146612.49 g·mol−1 |
Ligelizumab ( INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. [1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator. [2] [3]
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma [4] concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo. [5]